CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 330 enrolled
Drug / intervention
PrEP for Safer Conceptionbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03194308
NCT03194308Phase 4Completed

Safer Conception for Women: PrEP Uptake/Adherence to Reduce Periconception HIV Risk for South African Women

Massachusetts General Hospital·interventional·Posted Jun 21, 2017·Updated Oct 23, 2023

In Brief

A Phase 4 clinical trial evaluating PrEP for Safer Conception for HIV Prevention and Conception. Completed, enrolled 330 participants across 1 site.

Detailed Summary

Women who choose to conceive with an infected or unknown serostatus partner in HIV-endemic settings need prevention strategies to reduce periconception HIV acquisition risk. Women at high risk for acquiring HIV during pregnancy need risk reduction strategies to protect themselves and their babies. Evaluating uptake of and adherence to antiretrovirals as pre-exposure prophylaxis in this population is crucial to understanding whether and how this novel prevention strategy should be incorporated into HIV-risk reduction packages for at- risk women planning or with pregnancy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Africa

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJun 21, 2017
Enrollment StartNov 13, 2017
Primary CompletionJul 21, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.0 years ago

Interventions

PrEP for Safer Conceptionbehavioral

Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.